Chinese hamster ovary (CHO) cell lines are the preferred system for production of one of the most successful protein therapeutic classes—monoclonal antibodies. However, CHO cell line editing for research and commercial purposes appears to be a minefield, as there are numerous hurdles to overcome when editing CHO cell lines for optimized protein production. Challenges come about from the choice of editing technologies available (TALENS, Zinc Finger, CRISPR, rAAV, etc.), the intellectual property rights and freedom to operate implications surrounding the use of such technologies, and, last but by no means least, the level of expertise required to execute the editing of cell lines. Each editing technology comes with intricacies. For those companies with the knowledge and expertise specifically dedicated to developing new patient therapies and driving process efficiencies while reducing the cost of developing patient therapies, the last thing that is needed are further complexities as a barrier to success.

In this GEN webinar, we will hear about the gene-editing tools and options available at Horizon Discovery to customize the CHO expression host for both research and commercial use to suit specific needs during discovery, development, and protein production.


Jesus Zurdo low rez   Delphine Cugot, PhD

Jesus Zurdo, PhD
Global Head Cell, Gene Therapy & Bioproduction
Horizon Discovery

         Delphine Cugot
Senior Manager, Bioproduction         
Horizon Discovery

Webinar hosted by: GEN